

Contents

Chapter 1	Introduction and outline of the thesis Part 1 – Novel diagnostic strategies in low-risk MDS <i>Best Practice & Research Clinical Haematology 2015; 28(1): 14-21</i> (adapted)	4
Chapter 2	Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias <i>European Journal of Cancer 2016; 54(2): 49-56</i>	17
Chapter 3	Evaluation of granulocytic maturation in myelodysplastic syndromes, pathological controls and normal controls <i>Submitted</i>	32
Chapter 4	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes A report from the IMDSFlow Working Group <i>Haematologica 2017; 102(2): 308-319</i>	46
Chapter 5	Validation of diagnostic flow cytometric algorithms for myelodysplastic syndromes A study on behalf of the HOVON89 study group <i>Haematologica 2017; 102(2): 320-326</i>	75
Chapter 6	Conventional and emerging diagnostic techniques describe a heterogeneous landscape in low-intermediate-1 risk myelodysplastic syndromes <i>To be submitted in part of the clinical HOVON89 study</i>	93
Chapter 7	Introduction and outline of the thesis Part 2 – Red blood cell transfusion induced iron toxicity in low and high MDS <i>Nederlands Tijdschrift voor Hematologie 2014; 5(11): 215-221</i> (adapted)	115

Chapter 8	Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation <i>Annals of Hematology 2016; 96(12): 1971-1978</i>	120
Chapter 9	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic haematopoietic cell transplantation <i>Submitted</i>	133
Chapter 10	Discussion and future perspectives	149
Chapter 11	Summary in Dutch	155
Appendixes		
	Curriculum vitae	159
	List of publications	160
	Acknowledgments	162